

October 6, 2026

To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 59/26-27	Our Reference No. 59/26-27

Dear Sir/ Madam,

Sub: Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)

Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch¹ of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark's Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin^{®2} Gel, 0.1%.

According to Nielsen[®] syndicated data for the latest 52-week period ending September 5, 2026, the Differin[®] Gel, 0.1% (OTC) market³ achieved annual sales of approximately \$45.8 million*.

Kindly find attached media release which is self- explanatory.

Request you to take the same on record.

Thanking you.

For Glenmark Pharmaceuticals Limited

RASHMI
KHANDELWA
L

Digitally signed by
RASHMI KHANDELWAL
Date: 2026.10.06
08:29:40 +05'30'

Rashmi Khandelwal

Company Secretary & Compliance Officer

ACS – 28839

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)

Elmwood Park, New Jersey, October 06, 2026 – Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch¹ of Adapalene Gel USP, 0.1% (OTC) in new pump packs. Glenmark's Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin^{®2} Gel, 0.1%.

According to Nielsen[®] syndicated data for the latest 52-week period ending September 5, 2026, the Differin[®] Gel, 0.1% (OTC) market³ achieved annual sales of approximately \$45.8 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio. This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs."

For product information and how to purchase, please visit:

[Adapalene Gel USP, 0.1% - 15 g Pump on Amazon](#)

[Adapalene Gel USP, 0.1% - 45 g Pump on Amazon](#)

[Adapalene Gel USP, 0.1% - 15 g Pump on Walmart.com](#)

[Adapalene Gel USP, 0.1% - 45 g Pump on Walmart.com](#)

¹Glenmark's Adapalene Gel USP, 0.1% (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label.

²This product is not manufactured or distributed by Galderma Laboratories, L.P. and/or Galderma Holding S.A., distributor of DIFFERIN[®] Gel and owner of the registered trademark DIFFERIN[®], respectively. [Galderma does not make or license Glenmark's product.]

³Market includes brand and all available therapeutic equivalents. Note: IQVIA[®] data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for and will only be marketed for the indications listed in Glenmark's approved label, which may be different than the approved RLD indications.

*Nielsen[®] NIQ Discover; Syndicated Data for Period Ending September 5, 2026

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact:

India	United States
Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999 Adfactors PR glenmark.ihcp@adfactorspr.com +91 9535635461	Akhila Natarajan mediarelations@glenmarkpharma.com Danielle Hagen danielle@nahigianstrategies.com 202-365-6112